A targeted cancer drug helped patients with previously treated advanced or recurrent endometrial cancer live longer than those receiving standard chemotherapy in a phase 3 trial. Median overall survival was 19.0 months with sacituzumab tirumotecan, compared with 12.1 months in the chemotherapy group.
by Lee Ah Ra This article has been translated AI. Registration Number: Seoul, Ah01174 Registration Date: 2010.03.19 Date of issue: October 14, 2005 Editor: Im Ho-jun Title: Health Chosun Company Name: Health Chosun Co.Ltd Address: 30, Sejongdaero 21-gil, Jung-gu, Seoul Youth Protection Officer: Pyo…
In a late-stage trial, Merck’s Kelun-Biotech–partnered TROP2 antibody-drug conjugate sacituzumab tirumotecan, better known as sac- TMT, slashed the risk of death by 32% in a particularly challenging type of endometrial cancer—the first ADC to significantly improve overall survival and progression-free…
Family medicine physician Dr. Jessica Gray breaks down a promising new clinical trial for endometrial cancer treatment showing lower risk of death. Breakthrough endometrial cancer treatment shows promising results Family medicine physician Dr. Jessica Gray breaks down a promising new…
Merck’s sac-TMT cut death risk 32% in endometrial cancer and won FDA priority review for the indication. Read more here. - Phase 3 data for Merck's (MRK) sacituzumab tirumotecan (sac-TMT) showed that the antibody-drug conjugate reduced the risk of death by 32% in individuals…
A new drug is effective at decreasing recurrence of and death from endometrial cancer, a landmark international study shows. The drug, called sacituzumab tirumotecan (sac-TMT), attaches to a protein on the surface of tumor cells and then delivers a targeted…
Merck (MRK), on Monday, reported that Phase 3 of its experimental cancer drug Sacituzumab Tirumotecan (Sac-TMT) helped patients with advanced or recurrent endometrial cancer live longer than those receiving just chemotherapy. The results were presented at the European Society for Medical…
TroFuse-005 is the first and only global Phase 3 study of a TROP2 ADC to demonstrate improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in these patients who have received prior platinum-based chemotherapy and anti-PD-1/L1 immunotherapy Results from TroFuse…
Uterine fibroids are the most common benign tumors of the female reproductive system. They particularly occur among women in their 30s and 40s, and are estimated to affect up to 70 percent to 80 percent of women by age 50. Yet many never know they…
ORANGE, CA / ACCESS Newswire / October 15, 2026 / Unlike most cancers, endometrial cancer is rising in incidence and... EdenDx Assay Validated as Supportive Endometrial Cancer Triage Tool in Peer-Reviewed Study ORANGE, CA / ACCESS Newswire / October 15, 2026 / Unlike most cancers, endometrial cancer is rising in…
Uterine and endometrial cancer: rising rates, risk factors including hair relaxers, diagnosis and treatment.
An article joins this feed when it matches these terms. Each one is also a search of its own.